Biocompatibility and characteristics of theophylline/carboxymethyl chitosan microspheres for pulmonary drug delivery

Citric acid cross-linked β-cyclodextrins: A review of preparation and environmental/biomedical application

The β-cyclodextrins (β-CD) are biocompatible macrocyclic candidates for the preparation of various composites with enhanced functions. While nontoxic and biodegradable citric acid (CA) is the favorite crosslinking agent for fabricating hierarchical advanced structures. The carboxyl and hydroxyl groups on CA can serve as "structural bridges" and enhance the solubility of β-CD. Leading to the construction of CA cross-linked β-CD with marvelous complicated structures and targeted functions. Here, we directly categorized the grafted composite materials into two main types such as organic and inorganic materials. Particularly, some representative composite materials are listed and analyzed in detail according to their preparation, advantages of unique characteristics, as well as the possible applications in environmental and biomedical fields such as adsorption of pollutants, sensors, and biomedical applications.

Carboxymethyl Chitosan Modified Oxymatrine Liposomes for the Alleviation of Emphysema in Mice via Pulmonary Administration

Pulmonary emphysema is a fatal lung disease caused by the progressive thinning, enlargement and destruction of alveoli that is closely related to inflammation and oxidative stress. Oxymatrine (OMT), as a bioactive constituent of traditional Chinese herbal Sophora flavescens, has great potential to alleviate pulmonary emphysema via its anti-inflammatory and antioxidative activities. Pulmonary administration is the most preferable way for the treatment of lung diseases. To improve the in vivo stability and pulmonary retention of OMT, OMT-loaded liposome with carboxymethyl chitosan (CMCS) modification was developed. The CMCS was modified on the surface of OMT liposomes via electrostatic attraction and covalent conjugation to obtain Lipo/OMT@CMCS and CMCS-Lipo/OMT, respectively. A porcine pancreatic elastase (PPE)-induced emphysema mice model was established to evaluate the alleviation effects of OMT on alveolar expansion and destruction. CMCS-modified liposomal OMT exhibited superior ameliorative effects on emphysema regardless of the preparation methods, and higher sedimentation and longer retention in the lung were observed in the CMCS-Lipo group. The mechanisms of OMT on emphysema were related to the downregulation of inflammatory cytokines and the rebalancing of antioxidant/oxidation via the Nrf2/HO-1 and NF-κB/IκB-α signaling pathways, leading to reduced cell apoptosis. Moreover, the OMT liposomal preparations further enhanced its anti-inflammatory and antioxidative effects. In conclusion, pulmonary administration of OMT is a potential strategy for the treatment of emphysema and the therapeutic effects can be further improved by CMCS-modified liposomes.

Zinc ions coordinated carboxymethyl chitosan-hyaluronic acid microgel for pulmonary drug delivery

Microgel affords a porous and swollen microstructure for the establishment of pulmonary delivery system with sustained released properties. Here, we report a microgel (with the diameter around 4 μm) prepared with a precipitation method, synthesized by coordinating Zn²⁺ to the Schiff base cross-linked carboxymethyl chitosan and glycol split hyaluronate. The microgel has shown well swollen and pH sensitive behaviors, high safety and biocompatibility in vitro. Besides, the biomaterial could escape from macrophage phagocytosis, a key factor contribute to quick drug clearance in the lung after co-incubated with RAW 264.7 cells. In consist with this, the bovine serum albumin loaded in the microgel showed sustained release behavior in 24 h in vitro; meanwhile, the drug had a retention time up to 36 h in the lung and followed by clearance in ICR mice through pulmonary administration. Thus, our microgel platform provides a promising candidate for pulmonary drug delivery systems with controlled release rate.

Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases

Chitosan-loaded nanomedicines provide a greater opportunity for the treatment of respiratory diseases. Natural biopolymer chitosan and its derivatives have a large number of proven pharmacological actions like antioxidant, wound healing, immuno-stimulant, hypocholesterolemic, antimicrobial, obesity treatment, anti-inflammatory, anticancer, bone tissue engineering, antifungal, regenerative medicine, anti-diabetic and mucosal adjuvant, etc. which attracted its use in the pharmaceutical industry. As compared to other polysaccharides, chitosan has excellent mucoadhesive characteristics, less viscous, easily modified into the chemical and biological molecule and gel-forming property due to which the drugs retain in the respiratory tract for a longer period of time providing enhanced therapeutic action of the drug. Chitosan-based nanomedicines would have the greatest effect when used to transport poor water soluble drugs, macromolecules like proteins, and peptides through the lungs. In this review, we highlight and discuss the role of chitosan and its nanomedicines in the treatment of chronic respiratory diseases such as pneumonia, asthma, COPD, lung cancer, tuberculosis, and COVID-19.

Aspirin enhances the osteogenic and anti-inflammatory effects of human mesenchymal stem cells on osteogenic BFP-1 peptide-decorated substrates

Several bone diseases, including arthritis, fracture and osteoporosis, have a pathophysiologically important inflammatory component. Sustained inflammation can result in delayed bone healing. Therefore, to promote bone repair, it is important to inhibit inflammatory bone erosion and suppress pro-inflammatory mediators. In this study, aspirin significantly enhanced immunomodulation and osteogenic differentiation in human mesenchymal stem cells (hMSCs). Additionally, an osteogenic BFP-1 peptide-decorated substrate (PS-PEP) enhanced osteogenic differentiation of aspirin-treated hMSCs compared to a pristine substrate. Alkaline phosphatase assay, quantitative real-time polymerase chain reaction, immunostaining and Alizarin Red S staining revealed that aspirin-treated hMSCs cultured on PS-PEP exhibited enhanced osteogenesis compared with untreated cells. Thus, we report here that the anti-inflammatory and osteogenic effects of aspirin promote the activity and osteogenesis of hMSCs. The combination of aspirin and an osteogenic BFP-1 peptide-decorated substrate suppresses the production of pro-inflammatory mediators and promotes osteogenic differentiation of hMSCs; therefore, this novel strategy has potential for application in cell therapy and bone tissue engineering.

Recent advances in chitosan-based nanoparticulate pulmonary drug delivery

The advent of biodegradable polymer-encapsulated drug nanoparticles has made the pulmonary route of administration an exciting area of drug delivery research. Chitosan, a natural biodegradable and biocompatible polysaccharide has received enormous attention as a carrier for drug delivery. Recently, nanoparticles of chitosan (CS) and its synthetic derivatives have been investigated for the encapsulation and delivery of many drugs with improved targeting and controlled release. Herein, recent advances in the preparation and use of micro-/nanoparticles of chitosan and its derivatives for pulmonary delivery of various therapeutic agents (drugs, genes, vaccines) are reviewed. Although chitosan has wide applications in terms of formulations and routes of drug delivery, this review is focused on pulmonary delivery of drug-encapsulated nanoparticles of chitosan and its derivatives. In addition, the controversial toxicological effects of chitosan nanoparticles for lung delivery will also be discussed.